A Financial Ratio Quarterly Trend Analysis of:
Bristol-Myers Squibb Company
Stock symbol: BMY
Listed on the New York Stock Exchange
Introduction:
The following report will include provide a financial quarterly trend analysis of Bristol-Myers Squibb Company (BMS) which was founded in 1989, and is based in New York City. This is a publicly traded company on the New York Stock Exchange (NYSE), and their stock symbol is BMY.
Bristol-Myers Squibb is currently “ranked 8th among 500 the largest United States”1 manufacturers. The company is “engaged in the discovery, development, licensing, manufacturing, distribution and sale of pharmaceutical products on a global basis.”2
The types of medications they produce help “fight
…show more content…
|2.21 |2.08 |2.2 |2.29 |2.29 |
|Quick Ratio |1.99 |1.87 |1.98 |2.07 |2.07 |
|Net Working Capital Ratio |.25 |.21 |.23 |.25 |.25 |
|Current Liabilities to Inventory Ratio |4.47 |4.69 |4.67 |4.59 |4.59 |
|Cash Ratio |1.22 |.85 |1.0 |1.21 | 1.21 |
|Operating Ratio |2.81 |2.27 |2.2 |2.13 |2.34 |
|Asset Ratios |Q1 |Q2 |Q3 |Q4 |ANNUAL |
|Inventory Turnover Ratio |3.11 |3.09 |3.09 |3.01 |12.16 |
|Fixed Assets Turnover Ratio |.30 |.26 |.26 |0.27 |1.11 |
|Total Assets Ratio |.16 |.16 |0.16 |0.15 |.61 |
|Asset to Equity Ratio |2.09 |2.02 |2.02 |2.00
In 2008, Johnson & Johnson was named the 3rd best performing stock on the Dow Jones Industrial Average. It has uniquely positioned itself to remain a leader in a competitive industry against the rapidly changing backdrop of healthcare. The company’s main competitors are Eli Lilly, Novartis and
Pharma Co. should account for the restructuring program in different ways for the U.K parent and to U.S.-based lender.
Pfizer is the largest American pharmaceutical company and one of the largest pharmaceutical companies in the world. It competes with Merck and Glaxo, and markets such well-known medications as Celebrex and Viagra. However, the pharmaceutical industry as a whole has undergone changes in recent years with significant consolidation taking place and with increased scrutiny regarding the ways in which drugs are developed, tested and marketed. In addition, recent controversies have erupted regarding Merck's drug Vioxx, and Pfizer has been the target of unwanted publicity regarding its painkiller Celebrex. This research considers the strategic position of Pfizer, including its strengths and weaknesses as well
However, according to exhibit 7, the major product segment information of Lilly has shifted from 35% anti-infectives and 26% neurosciences in 1996 to 48% neurosciences and 24% endocrinology in 2000. While the major project segment of Ranbaxy remains in anti infectants from 49% in 1996 to 56% in 2000. This suggests that the conflict of product between the two companies was insignificant and therefore, from Eli lilly’s perspective, continuing the joint venture would be a good option.
Pharmacy benefit managers (PBMs) are companies that administer drug benefit programs for employers and health insurance carriers. PBMs contract with managed care organizations, self-insured employers, insurance companies, unions, Medicaid and Medicare managed care plans, the Federal Employees Health Benefits Program and other federal, state, and local government entities to provide managed prescription drug benefits.
The Pharmaceutical industry has been in the spotlight for decades due to the fact that they have a reputation for being unethical in its marketing strategies. In The Washington Post Shannon Brownlee (2008) states, “We try never to forget that medicine is for the people. It is not for the profits. The profits follow.” This honorable statement is completely lost in today’s world of pharmaceutical marketing tactics. These tactics are often deceptive and biased. Big Pharma consistently forgets their moral purpose and focuses primarily on the almighty dollar. Big Pharma is working on restoring their reputation by reforming their ethical code of conduct.
The main alternative products to memantine are a series of cholinesterase inhibitors. These include donepezil, sold under the brand name Aricept? , rivastigmine, sold under the brand name Exelon? , and galantamine, sold under Razadyne?. These drugs work by preventing the degradation of acetylcholine, which is a chemical useful for memory and thought. Since these drugs all work in a similar manner, scientist found no significant difference between the drugs in clinical trails. However, trials have shown that these drugs all work better in the earlier stages of
MedTech Pharmaceuticals began with great potential and knowledgeable individuals who could make this company a success. Doug Reynolds, founder of MedTech Pharmaceuticals had a vision; therefore, changing his position from research and venturing in a new direction seemed to be the right move (Johnston & Marshall, 2009). Additionally, Doug had the expertise in the drug makeup from his molecular biology background; thus, Doug chose to make two drug compounds to treat skin cancers (Johnston & Marshall, 2009).
The pharmaceutical industry includes companies that research, develop, market or distribute generic and branded drugs. The industry expanded during the 1980’s and drugs to treat heart disease and AIDS were prominent. Consumer demand for nutritional supplements and alternative medicine increased during the 1990’s with the Internet facilitating direct purchases of drugs. Advertising for direct consumption of pharmaceutical drugs became more prominent; pharmaceutical companies were criticized for over medicating personality or social problems.
AbbVie concentrates on patient taking into consideration the most difficult to treat diseases. It works in 170 Countries, with 25,000 employees with 15 research and manufacturing facilities around the world. Its
Unlike Gilead that has only one product in its Oncology line, Bristol-Myers Squibb presently have four different drugs namely: Erbitux –an epidermal growth factor receptor (EGFR) antagonist for the treatment of Head & Neck cancer and Colorectal cancer,(2) Opdivo (nivolumab) for the treatment of unresectable or metastic melanoma and lungs cancer, (3) Syrcel( dasatinb) for the treatment of newly diagnosed adult with Philadelphia chromosome –positive (ph+) chronic myeloid leukemia and (4) Yervoy (ipilimumob) for the treatment of melanoma a type of skin cancer that spread and as such cannot be remove by surgery. Like Seattle Genetics, the company products use either Antibody-drug Conjugate (ADC) though in a different version by linking potent cytotoxic to monoclonal antibodies targeted to specific tumor cells or immune-oncology, an innovative technology that unlocks the body own immune system to fight against cancerous cells. It also expanded its focus to Nolch inhibitor (used in blocking powerful pathway that promotes tumor cell survival for certain other types of cancer. (Bristol-Myer Squibb, 2014) Because the technology is similar but used differently, BMS would be considered a close competitor who currently has the advantage of having four targeted specific drugs and 12 other oncology and immune-oncology in various trial phases.
Pfizer is known as one of the first and one of the world’s largest Pharmaceutical company that was establish in 1849. It was founded by two cousins called Charles Pfizer and Charles F. Erhart in New York City. Pfizer was as a manufacturer for fine chemicals but because of the discovery that was made in 1950 which made the company the path towards becoming the research-based pharmaceutical that it is update. The product that was first produced was the palatable form of sautonin which was used to treat intestinal worm. The Headquarters of Pfizer is located in New York City, with its research headquarters in Groton, Connecticut, which is nowadays the top multinational corporation that is sold all over the world. It is ranked as the second in the US and Japan market, and Novartis in first place and Roche in third place. The Pfizer Inc. is consisted with a trademark that is called PFIZER. Because of Pfizer’s strategies, Pfizer
Ratios aside, the patent of its older product (mainly Zyprexa) will expire in 2011. However, the increased in the newer products that accounts for total sales has increased to 24% from 18% in
Merck and Co., Inc. was, in 1978, one of the biggest makers of physician endorsed sedates on the planet. Headquartered in Rahway, New Jersey, Merck followed its starting points to Germany in 1668 when Friedrich Jacob Merck obtained a pharmacist in the city of Darmstadt. More than three hundred years after the fact, Merck, having turned into an American firm, utilized more than 28,000 individuals and had operations everywhere throughout the world.
In 2005, Phillip (Phil) Landgraf faced several glaring problems in the financial performance of his company, BioPharma, Inc. The firm had experienced a steep decline in profits and very high costs at its plants in Germany and Japan. Landgraf, the company 's president for worldwide operations, knew that demand for the company 's products was stable across the globe. As a result, the surplus capacity in his global production network looked like a luxury he could no longer afford.